Your info buddies

Targeting IL-23 a Hit in Psoriatic Arthritis

Action Points

  • Note that this study was published as an abstract and presented at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal.
  • Not that this randomized trial of the anti-Il23 antibody guselkumab for the treatment of psoriatic arthritis found strong evidence of efficacy across many outcome metrics.
  • Overall, the novel medication appeared to be well-tolerated.

Read the full article from the Source…

Leave a Reply

Your email address will not be published. Required fields are marked *

WaterBuddys © 2017